Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig R Rayner

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
British Journal of Clinical Pharmacology|December 21, 2007
Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetusSreeja Sudhakaran, Craig R Rayner, Jian Li, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2015
A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progressionMohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, et al.
British Journal of Clinical Pharmacology|October 8, 2014
Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysisKashyap Patel, Craig R Rayner, Mylène Giraudon, et al.
Antimicrobial Agents and Chemotherapy|August 31, 2006
Heteroresistance to colistin in multidrug-resistant Acinetobacter baumanniiJian Li, Craig R Rayner, Roger L Nation, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2003
Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use programMary C Birmingham, Craig R Rayner, Alison K Meagher, et al.
British Journal of Clinical Pharmacology|December 29, 2020
Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2Kashyap Patel, Michael Dodds, Antonio Gonçalves, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2016
Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus ProgressionMohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, et al.
Antimicrobial Agents and Chemotherapy|August 19, 2015
Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approachMohamed A Kamal, Kayla Yi Ting Lien, Richard Robson, et al.
The Lancet. Infectious Diseases|August 26, 2006
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infectionsJian Li, Roger L Nation, John D Turnidge, et al.
Antimicrobial Agents and Chemotherapy|September 2, 2009
Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous systemGerhard Hoffmann, Christoph Funk, Stephen Fowler, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
British Journal of Clinical Pharmacology|December 21, 2007
Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetusSreeja Sudhakaran, Craig R Rayner, Jian Li, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2015
A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progressionMohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, et al.
British Journal of Clinical Pharmacology|October 8, 2014
Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysisKashyap Patel, Craig R Rayner, Mylène Giraudon, et al.
Antimicrobial Agents and Chemotherapy|August 31, 2006
Heteroresistance to colistin in multidrug-resistant Acinetobacter baumanniiJian Li, Craig R Rayner, Roger L Nation, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2003
Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use programMary C Birmingham, Craig R Rayner, Alison K Meagher, et al.
British Journal of Clinical Pharmacology|December 29, 2020
Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2Kashyap Patel, Michael Dodds, Antonio Gonçalves, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2016
Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus ProgressionMohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, et al.
Antimicrobial Agents and Chemotherapy|August 19, 2015
Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approachMohamed A Kamal, Kayla Yi Ting Lien, Richard Robson, et al.
The Lancet. Infectious Diseases|August 26, 2006
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infectionsJian Li, Roger L Nation, John D Turnidge, et al.
Antimicrobial Agents and Chemotherapy|September 2, 2009
Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous systemGerhard Hoffmann, Christoph Funk, Stephen Fowler, et al.
Pageof 7